Data / Form D filings / Zucara Therapeutics Inc.
Zucara Therapeutics Inc.: Form D filing
Zucara Therapeutics Inc., a biotechnology company in Toronto, Ontario, Canada, filed a Form D with the SEC in 2025. The latest, on March 6, 2025, reports $5 million sold of a $5 million offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1300-661 UNIVERSITY AVENUE, Toronto, Ontario, Canada, M5G 0
- Phone
- (416) 859-3978
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Canada (Federal Level)
- Revenue range
- $1 - $1,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2059295
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 6, 2025 | New notice | $4,999,978 | $4,999,978 | 3 | Feb 3, 2025 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Chris A Garabedian | Director | |
| Claude A Piche | Director | |
| Michael Midmer | Executive Officer, Director | |
| Michael A Martin | Director | |
| Richard A Liggins | Executive Officer | |
| Janet A Grove | Executive Officer | |
| Fred A Callori | Director |
Every Form D from the week of Mar 3, 2025 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Zucara Therapeutics Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.